

Hepatitis B Virus

**A Study of RO7239958 to Evaluate Safety, Tolerability,  
Pharmacokinetics and Pharmacodynamics in Healthy Volunteers and  
Participants With Chronic Hepatitis B Virus Infection**

**Trial Status**  
Terminated

**Trial Runs In**  
9 Countries

**Trial Identifier**  
NCT03762681 NP40520

---

*The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.*

***Trial Summary:***

This study is designed to assess the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of single and multiple ascending doses in healthy volunteers (HV) and participants diagnosed with chronic hepatitis B (CHB).

**Hoffmann-La Roche**  
Sponsor

**Phase 1**  
Phase

---

**NCT03762681 NP40520**  
Trial Identifiers

---

***Eligibility Criteria:***

**Gender**  
All

**Age**  
≥18 Years & ≤ 65 Years

**Healthy Volunteers**  
Accepts Healthy Volunteers

---